Sagitta is a proprietary molecular diagnostic platform based on our advanced molecular fingerprinting technology which can detect many DNA targets in a single tube reaction. Sagitta can directly amplify DNA targets in crude samples through qPCR (Polymerase Chain Reaction) and genotyping through HRM (High Resolution Melt) analysis using a single fluorescence channel. This technology has the capability of addressing many point-of-care (POC) models as well as high-throughput automation applications. Sagitta can be applied for the detection of viral, bacterial DNA and for tumor mutation typing directly from FFPE tissue samples (Formalin-Fixed Paraffin-Embedded).
The NanoHybrid is a unique DNA/PNA (Peptide Nucleic Acid) based multi-modal biomolecule amplifying platform that can detect specific antibodies and protein analytes, rapidly and quantitatively, directly from serum or whole blood. These nano-explorers allow POC medical devices and self-testing tools to detect viruses and tumors with reduced time, reduced cost and with unparalleled accuracy.
The NanoHybrid platform was also developed for the application of personalized medicine. This platform has recently demonstrated clinically relevant therapeutic drug monitoring (TDM) capabilities for a major oncology therapy, with a long list of other product prototypes in development. The NanoHybrid platform is also compatible with high- throughput automation applications, for the simultaneous analysis of hundreds of samples.
Pubblicazioni:
https://pubs.acs.org/doi/10.1021/jacs.7b09347
https://pubs.acs.org/doi/10.1021/acs.analchem.8b01584
Address
Administrative Department : Via Cavour 20 – 33100 UDINE
Laboratory : Area Science Park – S.S.14 km.163,5 – 34149 BASOVIZZA (TS)
ISO 9001 and ISO 13485 certified